Galderma Expands Alastin Line with TriHex+™-Powered Skin Nectar
Event summary
- Galderma launched Regenerating Skin Nectar with TriHex+™, an enhanced version of Alastin's peri-procedural skincare product.
- The new formulation includes Octapeptide-45 to support high-molecular-weight hyaluronic acid production and reinforce skin structure.
- Clinical studies showed 100% of patients improved key extracellular matrix markers after using the product pre-facelift.
- U.S. launch begins April 2026, with exclusive distribution through medical aesthetic practices.
The big picture
Galderma's launch of Regenerating Skin Nectar with TriHex+™ underscores the growing importance of peri-procedural skincare in aesthetic medicine. The product's clinical validation strengthens Alastin's position as a leader in regenerative dermatology, while Galderma's focus on extracellular matrix remodeling aligns with broader industry trends toward structural skin longevity solutions.
What we're watching
- Market Penetration
- Whether Galderma can sustain Alastin's leadership in peri-procedural skincare as it expands internationally.
- Clinical Adoption
- The pace at which dermatologists and plastic surgeons integrate TriHex+™ technology into pre- and post-procedure protocols.
- Competitive Differentiation
- How effectively Galderma positions Alastin against exosome-based products in microneedling applications.